Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine

Virology

Volumn 377, Issue 1, 2008, Pages 19-29

  Golden, Joseph W ^a   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

B cell epitope; Cross protection; DNA vaccine; Immunogen; Monoclonal antibody; Orthopoxviruses; Polyclonal antibody; Smallpox

Indexed keywords

AMINO ACID DERIVATIVE; DNA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10F10; MONOCLONAL ANTIBODY 1G10; MONOCLONAL ANTIBODY A33; PROTEIN A33; PROTEIN A35; SMALLPOX VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MORTALITY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SMALLPOX; WEIGHT REDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, VIRAL; BASE SEQUENCE; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; DNA, VIRAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SMALLPOX VACCINE; VACCINES, DNA; VARIOLA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

MONKEYPOX VIRUS; MUS; ORTHOPOXVIRUS; VARIOLA VIRUS;

EID: 44949199082     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.04.003     Document Type: Article

References (56)

1. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Hirao L., Isaacs S.N., Moss B., Eisenberg R.J., and Cohen G.H. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79 10 (2005) 6260-6271
2. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Pannell L.K., Lebowitz J., Fogg C., White C.L., Moss B., Cohen G.H., and Eisenberg R.J. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341 1 (2005) 59-71
3. Aldaz-Carroll L., Xiao Y., Whitbeck J.C., Ponce de Leon M., Lou H., Kim M., Yu J., Reinherz E.L., Isaacs S.N., Eisenberg R.J., and Cohen G.H. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J. Virol. 81 15 (2007) 8131-8139
4. Artenstein A.W., Johnson C., Marbury T.C., Morrison D., Blum P.S., Kemp T., Nichols R., Balser J.P., Currie M., and Monath T.P. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23 25 (2005) 3301-3309
5. Blasco R., Sisler J.R., and Moss B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol. 67 6 (1993) 3319-3325
6. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antivir. Res 58 2 (2003) 101-114
7. Bray M., and Buller M. Looking back at smallpox. Clin. Infect. Dis. 38 6 (2004) 882-889
8. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., and Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J. Am. Coll. Cardiol. 43 9 (2004) 1503-1510
9. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Yu F., Sebrell A., Emerson S., Cohen G., Eisenberg R.J., Gorshkova I., Schuck P., Satterfield W., Moss B., and Purcell R. Characterization of chimpanzee/human monoclonal antibodies to the vaccinia A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia mouse protection model. J. Virol. 81 17 (2007) 8989-8995
10. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., Boyd S.Y., Murphy J.G., Swerdlow D.L., Collins L.C., Riddle J.R., Tornberg D.N., Grabenstein J.D., and Engler R.J. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44 1 (2004) 201-205
11. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., and Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11 7 (2005) 740-747
12. Enserink M. Biodefense smallpox vaccines: looking beyond the next generation. Science 304 5672 (2004) 809
13. Fang M., Cheng H., Dai Z., Bu Z., and Sigal L.J. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345 1 (2006) 231-243
14. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78 19 (2004) 10230-10237
15. Fogg C.N., Americo J.L., Lustig S., Huggins J.W., Smith S.K., Damon I., Resch W., Earl P.L., Klinman D.M., and Moss B. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25 15 (2007) 2787-2799
16. Galmiche M.C., Goenaga J., Wittek R., and Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254 1 (1999) 71-80
17. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., Manischewitz J., King L.R., Hryniewicz A., Trindade C.J., Hassett M., Tsai W.P., Venzon D., Nalca A., Vaccari M., Silvera P., Bray M., Graham B.S., Golding H., Hooper J.W., and Franchini G. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177 4 (2006) 2552-2564
18. Hooper J.W., Custer D.M., Schmaljohn C.S., and Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266 2 (2000) 329-339
19. Hooper J.W., Custer D.M., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 1 (2003) 181-195
20. Hooper J.W., Schmaljohn A.L., and Schmaljohn C. Prophylactic and Therapeutic Monoclonal Antibodies. The United States of America as represented by the Secretary of the Army (2002) United States of America
21. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., Schmaljohn C.S., Schmaljohn A.L., and Jahrling P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78 9 (2004) 4433-4443
22. Hooper J.W., Golden J.W., Ferro A.M., and King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25 10 (2007) 1814-1823
23. Kretzschmar M., Wallinga J., Teunis P., Xing S., and Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 3 8 (2006) e272
24. Lane J.M., and Goldstein J. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 14 3 (2003) 189-195
25. Law M., Hollinshead R., and Smith G.L. Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J. Gen. Virol. 83 Pt 1 (2002) 209-222
26. Lustig S., Fogg C., Whitbeck J.C., and Moss B. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328 1 (2004) 30-35
27. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79 21 (2005) 13454-13462
28. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., Liu J., Gardner B., Downing G., Blum P.S., Kemp T., Nichols R., and Weltzin R. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8 Suppl 2, (2004) S31-S44
29. Moore Z.S., Seward J.F., and Lane J.M. Smallpox. Lancet 367 9508 (2006) 425-435
30. Moss B. Poxviruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. (2001), Lippencott, Williams and Wilkins, Philadelphia 1249-1281
31. Moss B. Poxvirus entry and membrane fusion. Virology 344 1 (2006) 48-54
32. Panchanathan V., Chaudhri G., and Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc. Natl. Acad. Sci. U. S. A. 102 36 (2005) 12921-12926
33. Panchanathan V., Chaudhri G., and Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80 13 (2006) 6333-6338
34. Panchanathan V., Chaudhri G., and Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol. Cell Biol. 86 1 (2008) 80-86
35. Parker S., Nuara A., Buller R.M., and Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2 (2007) 17-34
36. Payne L.G. Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J. Virol. 31 1 (1979) 147-155
37. Perdiguero B., and Blasco R. Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins. J. Virol. 80 17 (2006) 8763-8777
38. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A., Swain G.R., Olson V.A., Sargent E.K., Kehl S.C., Frace M.A., Kline R., Foldy S.L., Davis J.P., and Damon I.K. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350 4 (2004) 342-350
39. Resch W., Hixson K.K., Moore R.J., Lipton M.S., and Moss B. Protein composition of the vaccinia virus mature virion. Virology 358 1 (2007) 233-247
40. Rimoin A.W., Kisalu N., Kebela-Ilunga B., Mukaba T., Wright L.L., Formenty P., Wolfe N.D., Shongo R.L., Tshioko F., Okitolonda E., Muyembe J.J., Ryder R.W., and Meyer H. Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. Emerg. Infect. Dis. 13 6 (2007) 934-937
41. Roper R.L., Payne L.G., and Moss B. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J. Virol. 70 6 (1996) 3753-3762
42. Roper R.L., Wolffe E.J., Weisberg A., and Moss B. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol 72 5 (1998) 4192-4204
43. Rottger S., Frischknecht F., Reckmann I., Smith G.L., and Way M. Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation. J. Virol. 73 4 (1999) 2863-2875
44. Sakhatskyy P., Wang S., Chou T.H., and Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355 2 (2006) 164-174
45. Sakhatskyy P., Wang S., Zhang C., Chou T.H., Kishko M., and Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 37 1 (2008) 89-107
46. Schmaljohn C., Vanderzanden L., Bray M., Custer D., Meyer B., Li D., Rossi C., Fuller D., Fuller J., Haynes J., and Huggins J. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J. Virol. 71 12 (1997) 9563-9569
47. Smith G.L., and Vanderplasschen A. Extracellular enveloped vaccinia virus entry, egress, and evasion. Adv. Exp. Med. Biol. 440 (1998) 395-414
48. Smith G.L., Vanderplasschen A., and Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83 Pt 12 (2002) 2915-2931
49. Su H.P., Golden J.W., Gittis A.G., Hooper J.W., and Garboczi D.N. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 368 (2007) 331-341
50. Vanderplasschen A., Hollinshead M., and Smith G.L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78 Pt 8 (1997) 2041-2048
51. Vanderplasschen A., and Smith G.L. A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J. Virol. 71 5 (1997) 4032-4041
52. Wharton M., Strikas R.A., Harpaz R., Rotz L.D., Schwartz B., Casey C.G., Pearson M.L., and Anderson L.J. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morb. Mort. Wkly. Rep., Recomm. Rep. 52 RR-7 (2003) 1-16
53. Wolffe E.J., Vijaya S., and Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211 1 (1995) 53-63
54. Wolffe E.J., Weisberg A.S., and Moss B. The vaccinia virus A33R protein provides a chaperone function for viral membrane localization and tyrosine phosphorylation of the A36R protein. J. Virol. 75 1 (2001) 303-310
55. Wollenberg A., Wetzel S., Burgdorf W.H., and Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J. Allergy Clin. Immunol. 112 4 (2003) 667-674
56. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., Davis H.L., Braciale T.J., Eisenberg R.J., Cohen G.H., and Isaacs S.N. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25 7 (2007) 1214-1224